|
|
||||||||
Departments of Radiology and Cardiology, Mayo Clinic, Rochester, Minnesota
Department of Nuclear Medicine, William Beaumont Hospital, Royal Oak, Michigan
Cardiovascular Consultants, Kansas City, Missouri
Department of Nuclear Medicine, Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois
Correspondence: For correspondence or reprints contact: Dr. M.K. O'Connor, Section of Nuclear Medicine, Charlton 2, Mayo Clinic, Rochester, MN 55905.
ABSTRACT
This study determined the feasibility of performing a multicenter trial using quantitative SPECT myocardial perfusion imaging in patients with acute myocardial infarction. The feasibility was assessed by a cardiac phantom. Methods: Twenty-two gamma camera systems in 19 laboratories were evaluated. Each laboratory performed nine studies on the cardiac phantom and performed quality control tests of system uniformity, collimator quality and gantry alignment on their gamma camera system. Defects simulating "hypoperfused" myocardium of differing amounts were placed in the myocardium for eight of the nine studies. Measured defect size was compared to true defect size. Results: A total of 198 studies from 22 systems were analyzed. Three studies were technically inadequate. For all 22 systems, the average correlation coefficient between true and measured defect size was 0.992 ± 0.009, with a range from 1.00 to 0.97. Three systems were rejected due to slopes of the regression line outside the limits 1.00 ± 0.10 and mean errors >5% in estimating defect size. The remaining systems had a correlation coefficient of 0.995 + 0.008 with an average slope of 1.00 ± 0.04 and an intercept of 0.11% ± 1.57%. The mean error in estimating defect size was 2.08% ± 0.69%. Conclusion: The small interlaboratory variation and the close correlation with true defect size observed in a cardiac phantom indicate the feasibility of quantitative myocardial SPECT as a useful tool in multicenter trials evaluating therapy in acute myocardial infarction. Preliminary objective testing is required, however, to identify systems with technical deficiencies.
Key Words: technetium-99m-sestamibi cardiac phantom infarct sizing single-photon emission computed tomography
This article has been cited by other articles:
![]() |
T. Ibrahim, H. P. Bulow, T. Hackl, M. Hornke, S. G. Nekolla, M. Breuer, A. Schomig, and M. Schwaiger Diagnostic Value of Contrast-Enhanced Magnetic Resonance Imaging and Single-Photon Emission Computed Tomography for Detection of Myocardial Necrosis Early After Acute Myocardial Infarction J. Am. Coll. Cardiol., January 16, 2007; 49(2): 208 - 216. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Pereztol-Valdes, J. Candell-Riera, C. Santana-Boado, J. Angel, S. Aguade-Bruix, J. Castell-Conesa, E. V. Garcia, and J. Soler-Soler Correspondence between left ventricular 17 myocardial segments and coronary arteries Eur. Heart J., December 2, 2005; 26(24): 2637 - 2643. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Ndrepepa, A. Kastrati, M. Schwaiger, J. Mehilli, C. Markwardt, A. Dibra, J. Dirschinger, and A. Schomig Relationship Between Residual Blood Flow in the Infarct-Related Artery and Scintigraphic Infarct Size, Myocardial Salvage, and Functional Recovery in Patients with Acute Myocardial Infarction J. Nucl. Med., November 1, 2005; 46(11): 1782 - 1788. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Ross, R. J. Gibbons, G. W. Stone, R. A. Kloner, R. W. Alexander, and for the AMISTAD-II Investigators A Randomized, Double-Blinded, Placebo-Controlled Multicenter Trial of Adenosine as an Adjunct to Reperfusion in the Treatment of Acute Myocardial Infarction (AMISTAD-II) J. Am. Coll. Cardiol., June 7, 2005; 45(11): 1775 - 1780. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. W. Stone, J. Webb, D. A. Cox, B. R. Brodie, M. Qureshi, A. Kalynych, M. Turco, H. P. Schultheiss, D. Dulas, B. D. Rutherford, et al. Distal Microcirculatory Protection During Percutaneous Coronary Intervention in Acute ST-Segment Elevation Myocardial Infarction: A Randomized Controlled Trial JAMA, March 2, 2005; 293(9): 1063 - 1072. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. J. Gibbons, U. S. Valeti, P. A. Araoz, and A. S. Jaffe The quantification of infarct size J. Am. Coll. Cardiol., October 19, 2004; 44(8): 1533 - 1542. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Kastrati, J. Mehilli, K. Schlotterbeck, F. Dotzer, J. Dirschinger, C. Schmitt, S. G. Nekolla, M. Seyfarth, S. Martinoff, C. Markwardt, et al. Early Administration of Reteplase Plus Abciximab vs Abciximab Alone in Patients With Acute Myocardial Infarction Referred for Percutaneous Coronary Intervention: A Randomized Controlled Trial JAMA, February 25, 2004; 291(8): 947 - 954. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. P. Faxon, R. J. Gibbons, N. A. F. Chronos, P. A. Gurbel, F. Sheehan, and HALT-MI Investigators The effect of blockade of the CD11/CD18 integrin receptor on infarct size in patients with acute myocardial infarction treated with direct angioplasty: the results of the HALT-MI study J. Am. Coll. Cardiol., October 2, 2002; 40(7): 1199 - 1204. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Liu, G. A. Kastis, G. D. Stevenson, H. H. Barrett, L. R. Furenlid, M. A. Kupinski, D. D. Patton, and D. W. Wilson Quantitative Analysis of Acute Myocardial Infarct in Rat Hearts with Ischemia-Reperfusion Using a High-Resolution Stationary SPECT System J. Nucl. Med., July 1, 2002; 43(7): 933 - 939. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. J. Burns, R. J. Gibbons, Q. Yi, R. S. Roberts, T. D. Miller, G. L. Schaer, J. L. Anderson, S. Yusuf, and CORE Study Investigators The relationships of left ventricular ejection fraction, end-systolic volume index and infarct size to six-month mortality after hospital discharge following myocardial infarction treated by thrombolysis J. Am. Coll. Cardiol., January 2, 2002; 39(1): 30 - 36. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Matsunari, T. Yoneyama, S. Kanayama, M. Matsudaira, K. Nakajima, J. Taki, S. G. Nekolla, N. Tonami, and K. Hisada Phantom Studies for Estimation of Defect Size on Cardiac 18F SPECT and PET: Implications for Myocardial Viability Assessment J. Nucl. Med., October 1, 2001; 42(10): 1579 - 1585. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Schomig, A. Kastrati, J. Dirschinger, J. Mehilli, U. Schricke, J. Pache, S. Martinoff, F.-J. Neumann, M. Schwaiger, and The Stent versus Thrombolysis for Occluded Coronar Coronary Stenting plus Platelet Glycoprotein IIb/IIIa Blockade Compared with Tissue Plasminogen Activator in Acute Myocardial Infarction N. Engl. J. Med., August 10, 2000; 343(6): 385 - 391. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. J. Gibbons, T. D. Miller, and T. F. Christian Infarct Size Measured by Single Photon Emission Computed Tomographic Imaging With 99mTc-Sestamibi : A Measure of the Efficacy of Therapy in Acute Myocardial Infarction Circulation, January 4, 2000; 101(1): 101 - 108. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. W. Mahaffey, J. A. Puma, N. A. Barbagelata, M. F. DiCarli, M. A. Leesar, K. F. Browne, P. R. Eisenberg, R. Bolli, A. C. Casas, V. Molina-Viamonte, et al. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: Results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of ADenosine (AMISTAD) Trial J. Am. Coll. Cardiol., November 15, 1999; 34(6): 1711 - 1720. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. L. Schaer, L. J. Spaccavento, K. F. Browne, K. A. Krueger, D. Krichbaum, J. M. Phelan, W. O. Fletcher, C. L. Grines, S. Edwards, M. K. Jolly, et al. Beneficial Effects of RheothRx Injection in Patients Receiving Thrombolytic Therapy for Acute Myocardial Infarction: Results of a Randomized, Double-Blind, Placebo-Controlled Trial Circulation, August 1, 1996; 94(3): 298 - 307. [Abstract] [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |